Unleash Immuno Oncolytics

Unleash IO develops oncolytic immunotherapy products shown to be highly specific and efficacious in animal models and human tissue samples. Unleash IO’s leading product, UIO-512, is an oncolytic adenovirus that targets both malignant cells and tumor-associated stroma cells. UIO-512 is armed with GM-CSF, a potent immune-modulatory cytokine, triggering an immune response towards the tumor. UIO-512 lead indication is in ovarian cancer, follow on indications include other solid tumors such as glioblastoma, melanoma and pancreatic cancer. Promising pre-clinical results in animal models and fresh human samples of ovarian cancers as well as in melanoma were published in top ranked peer-reviewed publications. Unleash IO is raising $3.5 M to conduct a phase I/II clinical trial in ovarian cancer with oncolytic immunotherapy UIO-512.